Acipimox

阿昔莫司

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAcipimox
Drug Alias Name阿西莫司acipimoxum阿西英司乐脂平Olbetam +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHydroxycarboxylic acid receptor 2 agonists
TargetsHydroxycarboxylic acid receptor 2
Therapy Area/IndicationsBulimia NervosaFeeding and Eating DisordersHypertriglyceridemia +[9] 
Global Approved IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemias
Approved Indications in ChinaHypertriglyceridemiaHypercholesterolemiaHyperlipidemias
Original Approved Country/TerritoryMainland China
Original Approved Date2001/01/01
Country/TerritoryUnited StatesDenmarkAustria +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesCharles University, Czech RepublicDi'Ao Group Chengdu Pharmaceutical Co Ltd
Inactive CompaniesThe Brigham and Women's HospitalAarhus UniversityUniversity Of Colorado Denver +[4] 
Active IndicationsBulimia NervosaFeeding and Eating DisordersHypertriglyceridemia +[5] 
Inactive IndicationsMetabolic SyndromeDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[4] 

Other Information

ATC CodeC10AD06
Related LinksWikipediaKEGG